Search Results - "Merlini G"

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial.

Authors: Brannagan, T. H. Wang, A. K. Coelho, T. et al.

Source: European Journal of Neurology. Aug2020, Vol. 27 Issue 8, p1374-1381. 8p. 1 Diagram, 2 Charts, 3 Graphs.

Subjects: Patient safety, Amyloidosis, Diabetic neuropathies, Neurological disorders, Peripheral nervous system

Geographic Terms: Norfolk (Va.)

This result is not displayed to guests.
Login for full access.

The systemic amyloidoses: clearer understanding of the molecular mechanisms offers hope for more effective therapies.

Authors: Merlini G Westermark P Merlini, G et al.

Source: Journal of Internal Medicine. Feb2004, Vol. 255 Issue 2, p159-178. 20p.

URL: 12046521

Mechanisms of disease: molecular mechanisms of amyloidosis.

Authors: Merlini G Bellotti V

Source: New England Journal of Medicine. 8/7/2003, Vol. 349 Issue 6, p583-596. 14p.

An IgM monoclonal protein with multiple serological specificities.

Authors: Merlini, G. Forsgren, A. Turesson, I. et al.

Source: Clinical & Experimental Immunology. Aug1979, Vol. 37 Issue 2, p276-282. 7p.

A sulfhydryl-rich IgM protein with multiple serological specificities.

Authors: Merlini, G. Zettervall, O. Forsgren, A. et al.

Source: Clinical & Experimental Immunology. Jul1987, Vol. 69 Issue 1, p148-156. 9p.

International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors: Dispenzieri, A. Kyle, R. Merlini, G. et al.

Source: Leukemia (08876924). Feb2009, Vol. 23 Issue 2, p215-224. 10p. 1 Diagram, 5 Charts, 3 Graphs.

Amyloidosis: is a cure possible?

Authors: Merlini, G. Palladini, G.

Source: Annals of Oncology. Jun2008 Supplement 4, Vol. 19, piv63-iv66. 1p. 1 Graph.

Diagnosis, treatment, and response assessment in solitary plasmacytoma: updated recommendations from a European Expert Panel.

Authors: Caers, J. Paiva, B. Zamagni, E. et al.

Source: Journal of Hematology & Oncology. 1/16/2018, Vol. 11, p1-N.PAG. 10p.

Melphalan and dexamethasone with or without bortezomib in newly diagnosed AL amyloidosis: a matched case-control study on 174 patients.

Authors: Palladini, G Milani, P Foli, A et al.

Source: Leukemia (08876924). Dec2014, Vol. 28 Issue 12, p2311-2316. 6p. 2 Charts, 3 Graphs.

New drugs and novel mechanisms of action in multiple myeloma in 2013: a report from the International Myeloma Working Group (IMWG).

Authors: Ocio, E M Richardson, P G Rajkumar, S V et al.

Source: Leukemia (08876924). Mar2014, Vol. 28 Issue 3, p525-542. 18p.

Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis.

Authors: Comenzo, R L Reece, D Palladini, G et al.

Source: Leukemia (08876924). Nov2012, Vol. 26 Issue 11, p2317-2325. 9p. 4 Charts, 2 Graphs.

Management of treatment-emergent peripheral neuropathy in multiple myeloma.

Authors: Richardson, P G Delforge, M Beksac, M et al.

Source: Leukemia (08876924). Apr2012, Vol. 26 Issue 4, p595-608. 14p. 4 Charts.

Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management.

Authors: Kyle, R. A. Durie, B. G. M. Rajkumar, S. V. et al.

Source: Leukemia (08876924). Jun2010, Vol. 24 Issue 6, p1121-1127. 7p. 3 Charts, 1 Graph.

International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100).

Authors: Giralt, S. Stadtmauer, E. A. Harousseau, J. L. et al.

Source: Leukemia (08876924). Oct2009, Vol. 23 Issue 10, p1904-1912. 9p. 5 Charts.

Biological features of the clone involved in primary amyloidosis (AL).

Authors: Perfetti, V Vignarelli, M Colli Casarini, S et al.

Source: Leukemia (08876924). Feb2001, Vol. 15 Issue 2, p195-202. 8p.

Cells with clonal light chains are present in peripheral blood at diagnosis and in apheretic stem cell harvests of primary amyloidosis.

Authors: Perfetti, V Ubbiali, P Magni, M et al.

Source: Bone Marrow Transplantation. 2/15/99, Vol. 23 Issue 4, p323. 5p.

Scintigraphic imaging and turnover studies with iodine-131 labelled serum amyloid P component in systemic amyloidosis.

Authors: Hawkins, P. N. Aprile, C. Capri, G. et al.

Source: European Journal of Nuclear Medicine. 1998, Vol. 25 Issue 7, p701-708. 8p.

Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis.

Authors: Benson, M. D. Waddington-Cruz, M. Berk, J. L. et al.

Source: New England Journal of Medicine. 7/5/2018, Vol. 379 Issue 1, p22-31. 10p.

Hereditary amyloidosis.

Authors: Palladini G Obici L Merlini G et al.

Source: New England Journal of Medicine. 10/10/2002, Vol. 347 Issue 15, p1206-1207. 2p.